In settings were neither malaria nor severe bacterial infections are highly prevalent, CPT is recommended for PLHIV with severe or advanced HIV disease (WHO clinical stage 3 or 4, or CD4 count below 350 cells/mm3) and may be discontinued for those with evidence of immune recovery or viral suppression on antiretroviral treatment (ART). The gene discussed is CD4; the disease is malaria.